Angela is an Associate Professor in the Department of Biological Engineering at MIT and an Associate Director of the David H. Koch Institute for Integrative Cancer Research at MIT. She is also a member of the MIT Center for Cancer Precision Medicine and an Institute Member of the Broad Institute. The Koehler Lab aims to innovate in the earliest stages of drug discovery by building chemical tools or technologies to assist in the process of target validation and by expanding the repertoire of protein targets that are considered to be druggable. In recent years, the lab has focused on targeting transcription factors, RNA-binding proteins, and cytokines. Angela received her B.A. in Biochemistry and Molecular Biology from Reed College in 1997. In 2003, she received her Ph.D. in Chemistry from Harvard University in the laboratory of Professor Stuart Schreiber and became an Institute Fellow at the Broad Institute as well as Group Leader for the Harvard NCI Initiative for Chemical Genetics. Angela serves as the Faculty Director of the High-Throughput Sciences Facility in the Swanson Biotechnology Center. She is a co-Director of the MIT Biomedical Engineering Undergraduate Program. Angela has served on the Chemists in Cancer Research Executive Advisory Board for AACR. Awards include being named a Genome Technology Young Investigator and a Broad Institute Merkin Fellow as well as the Novartis Lectureship in Chemistry, the Ono Pharma Breakthrough Science Award, the AACR-Bayer Innovation and Discovery Award, the Mark Foundation ASPIRE Award and the MIT Junior Bose Award for Excellence in Teaching. Angela serves as a consultant or scientific advisory board member to several pharmaceutical or biotechnology companies and has founded multiple biotechnology companies, including Ligon Discovery, 76Bio, and Kronos Bio.